A Multicenter Phase II Trial of Ruxolitinib for Treatment of Corticosteroid Refractory Sclerotic Chronic Graft-Versus-Host Disease Article (Faculty180)

cited authors

  • Bhatt, Vijaya Ra R; Shostrom, Valerie K; Choe, Hannah K; Hamilton, Betty K; Gundabolu, Krishna; Maness, Lori J; Kumar, Virender; Mahato, Ram I; Smith, Lynette M; Nishihori, Taiga; Lee, Stephanie J

description

  • Sclerotic chronic graft-versus-host disease (cGVHD) represents a highly morbid and refractory form of cGVHD, and novel therapies for sclerotic cGVHD are critically needed. This study aimed to determine the efficacy of ruxolitinib in patients with corticosteroid refractory sclerotic cGVHD.

authors

publication date

  • 2024

published in

start page

  • JCO2400205